14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
VTYX Captures Overall Composite Edge (50.4 HOLD vs 58.3 HOLD), While DAWN Leads 3–2 on Growth & Valuation Pillars
VTYX Overall Winner
6-Pillar Tally: VTYX 2 – 3 DAWN (1 Tie)
Matrix Metrics: VTYX 2 – 6 DAWN
As of Apr 22, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Day One Biopharmaceuticals, Inc. (DAWN) on higher Unified Composite conviction (50.4/100 HOLD vs. 58.3/100 HOLD) after splitting the core matrix 2–6 (led by Profitability & Quality, Options & Positioning), while DAWN wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus DAWN at $21.53 (N/M Forward P/E, -51.1% operating margin).
Composite vs. Pillar Nuance: While DAWN currently prints a higher short-term Unified Composite Score (58.3/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51.1% operating margin) and revenue trajectory (+0.0% vs. +83.9% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs DAWN. Trailing 12-month operating profitability (VTYX 0.0% vs DAWN -51.1%) and valuation multiples (VTYX N/M vs DAWN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
DAWN Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -51.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VTYX vs DAWN Key Questions & Quantitative Answers
As of Apr 22, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Day One Biopharmaceuticals, Inc. (DAWN) on higher Unified Composite conviction (50.4/100 HOLD vs. 58.3/100 HOLD) after splitting the core matrix 2–6 (led by Profitability & Quality, Options & Positioning), while DAWN wins 3–2 across the 6-pillar growth and valuation breakdown. VTYX trades at $14.00 (N/M Forward P/E, 0.0% operating margin) versus DAWN at $21.53 (N/M Forward P/E, -51.1% operating margin). Composite vs. Pillar Nuance: While DAWN currently prints a higher short-term Unified Composite Score (58.3/100 HOLD vs. VTYX 50.4/100 HOLD), VTYX captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51.1% operating margin) and revenue trajectory (+0.0% vs. +83.9% YoY).
DAWN leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DAWN at +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $158M for DAWN. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DAWN.
DAWN screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus DAWN (-22.7% ROE) capital efficiency.
In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Apr 22, 2026. For educational research only; not investment advice.